Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary

Documenti analoghi

• Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
  di: Peter Batar, et al.
  Pubblicazione: (2024-03-01)
• Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption
  di: Judit Demeter, et al.
  Pubblicazione: (2021-02-01)
• WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
  di: İbrahim C. Haznedaroğlu, et al.
  Pubblicazione: (2020-02-01)
• Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?
  di: Avital F. Barak, et al.
  Pubblicazione: (2011-12-01)
• The Mechanisms of Resistance to Tyrosine Kinase Inhibitor Imatinib Therapy of Chronic Myeloid Leukemia
  di: S. I. Kutsev, et al.
  Pubblicazione: (2010-06-01)